Wolverine Trading
CRSP icon

Wolverine Trading’s CRISPR Therapeutics CRSP Stock Holding History

Wolverine Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,081
Closed -$780K – 4906
2025
Q1 		$780K Sell
21,081
-28,466
-57% -$1.21M ﹤0.01% 2485
2024
Q4 		$1.91M Buy
49,547
+33,647
+212% +$1.59M ﹤0.01% 1999
2024
Q3 		$752K Sell
15,900
-1,579
-9% -$80.1K ﹤0.01% 2649
2024
Q2 		$944K Sell
17,479
-12,008
-41% -$695K ﹤0.01% 2233
2024
Q1 		$2.01M Buy
29,487
+9,564
+48% +$685K ﹤0.01% 1615
2023
Q4 		$1.25M Buy
19,923
+863
+5% +$47.7K ﹤0.01% 2094
2023
Q3 		$865K Buy
19,060
+5,059
+36% +$261K ﹤0.01% 2231
2023
Q2 		$798K Buy
14,001
+9,460
+208% +$537K ﹤0.01% 2186
2023
Q1 		$201K Sell
4,541
-885
-16% -$43K ﹤0.01% 3408
2022
Q4 		$221K Buy
5,426
+1,754
+48% +$93K ﹤0.01% 3046
2022
Q3 		$237K Sell
3,672
-3,140
-46% -$228K ﹤0.01% 3399
2022
Q2 		$429K Sell
6,812
-16,224
-70% -$954K ﹤0.01% 2694
2022
Q1 		$1.48M Sell
23,036
-16,150
-41% -$1.01M ﹤0.01% 2046
2021
Q4 		$3.09M Buy
39,186
+5,858
+18% +$512K ﹤0.01% 1501
2021
Q3 		$3.67M Sell
33,328
-16,474
-33% -$2.07M ﹤0.01% 1554
2021
Q2 		$7.5M Sell
49,802
-11,949
-19% -$1.45M 0.01% 845
2021
Q1 		$7.11M Buy
61,751
+27,504
+80% +$4.15M 0.01% 891
2020
Q4 		$5.53M Buy
34,247
+18,512
+118% +$2.19M 0.01% 996
2020
Q3 		$1.34M Sell
15,735
-6,221
-28% -$552K ﹤0.01% 1796
2020
Q2 		$1.65M Buy
21,956
+4,583
+26% +$268K ﹤0.01% 1566
2020
Q1 		$769K Buy
17,373
+3,816
+28% +$197K ﹤0.01% 2190
2019
Q4 		$838K Buy
+13,557
New +$740K ﹤0.01% 2580
2018
Q4 		– Sell
-16,571
Closed -$576K – 4559
2018
Q3 		$735K Buy
+16,571
New +$868K ﹤0.01% 2669

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wolverine Trading's CRSP Position: Q2 2025 in Review

Wolverine Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 21,081 shares — an estimated $780K sold.

Wolverine Trading first reported a position in CRSP in Q3 2018 and held it in 23 quarters. The position peaked at $7.5M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Wolverine Trading reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 21,081 CRISPR Therapeutics shares in Q2 2025, an estimated $780K.
  • Wolverine Trading first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 23 quarters.
  • Wolverine Trading's CRISPR Therapeutics position peaked at $7.5M in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.